Health News

The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), a rare genetic disorder. This approval was for treatments of SEGA that can not be treated with surgery.

Read more

Filed under: Pharmacy News
Tags: cancer, Drug, Genetic, Pharmacy, sclerosis, Surgery

Related posts

• Viral Genetics Updates HIV/AIDS And Drug Resistant Cancer Research Programs (0)
  Viral Genetics, Inc. (Pinksheets: VRAL) continues to make the transition to a clinical-stage company. The Company's two lead pharmaceutical programs -- APi1177 for HIV/AIDS, and various Metabolic Disruption (MDT) compounds for drug-resistant cancers -- are being advanced towards clinical development under sponsor- or investigator-initiated Investigational New Drug (IND) pathways... Read more [tags] Pharmacy News [/tags]
  
  
• Viral Genetics cautions investors and the public to rely only on its press releases and disclosures (0)
  Viral Genetics (Pink Sheets: VRAL), a biotechnology company that develops drug compounds for HIV/AIDS, autoimmune diseases, and cancer, is issuing this announcement in response to a series of press releases distributed by collegestock.com on August 25 and August 26, and an article published on Today's Financial News entitled "TFN Reader Grapevine: There's Something About Viral [...]
  
  
• Study pinpoints compounds that repress cancer gene’s activity (0)
  A research team pursuing one of the most commonly altered genes in cancer has laid a critical foundation for understanding this gene that could point the way toward developing drugs against it. A recent study of cancer genetics pointed to the gene MCL1, which encodes a protein that helps keep cells alive Read more [tags] Pharmacy News [...]
  
  
• Study finds Olaparib can reduce tumor size in ovarian cancer women (0)
  Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations. Read [...]
  
  
• Study finds link between genetic variation and cetuximab rectal cancer therapy (0)
  team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can be cured by certain chemotherapies when combined with surgery. Read more [tags] Pharmacy News [/tags]